ResMed CEO exercises options, sells 4,991 shares
ResMed Inc. Chairman and CEO Michael J. Farrell exercised 4,991 options for ResMed Common Stock at an exercise price of $146.34 per share and acquired the same number of shares on August 7, 2026.
Rhea-AI Filing Summary
ResMed Inc. Chairman and CEO Michael J. Farrell exercised 4,991 options for ResMed Common Stock at an exercise price of $146.34 per share and acquired the same number of shares on August 7, 2026. He then sold 4,991 shares of ResMed Common Stock at a weighted average price of $205.6895 per share, with individual trades ranging from $202.410 to $204.160. The option exercise and related sale were conducted under a Rule 10b5-1 plan adopted October 31, 2024. Following the option transaction, he held 14,975 ResMed Common Stock options and had an indirect holding of 2,090 ResMed Common Stock shares through the Lisette and Michael Farrell Family Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,991 shares ($296K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Farrell Michael J.
Role
Chairman and CEO
Sold
4,991 shs ($1.03M)
Approx. gross sale proceeds
$1.03M
Approx. exercise cost
$730K
Approx. pre-tax spread
$296K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | ResMed Common Stock Options F1, F3 | 4,991 | $0.00 | $0.00 |
| Exercise | ResMed Common Stock F1 | 4,991 | $146.34 | $730K |
| Sale | ResMed Common Stock F1, F2 | 4,991 | $205.6895 | $1.03M |
| holding | ResMed Common Stock | -- | -- | -- |
Holdings After Transaction:
ResMed Common Stock Options — 14,975 contracts (Direct);
ResMed Common Stock — 466,256 shares (Direct);
ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)
Footnotes (3)
- F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- F2. This transaction was executed in multiple trades at prices ranging from $202.410 - $204.160. The price reported above reflects the weighted average sale price.
- F3. Represents date options first become exercisable. Options vest 1/3 per year.
Key Figures
Options Exercised: 4,991 shares
Option Exercise Price: $146.34 per share
Shares Sold: 4,991 shares
+5 more
8 metrics
Options Exercised
4,991 shares
ResMed Common Stock options exercised on August 7, 2026
Option Exercise Price
$146.34 per share
Conversion or exercise price for 4,991 ResMed options
Shares Sold
4,991 shares
ResMed Common Stock sold on August 7, 2026
Weighted Average Sale Price
$205.6895 per share
Weighted average for multiple trades in the sale transaction
Sale Price Range
$202.410–$204.160 per share
Range of prices for individual trades in the sale
Options Held After Exercise
14,975 options
Total ResMed Common Stock options following the option transaction
Indirect Shares in Family Trust
2,090 shares
ResMed Common Stock held indirectly via Lisette and Michael Farrell Family Trust
Option Expiration Date
November 21, 2026
Expiration for the exercised ResMed Common Stock options
Key Terms
Rule 10b5-1 plan, weighted average sale price, ResMed Common Stock Options, indirect ownership
4 terms
Rule 10b5-1 plan regulatory
"The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
ResMed Common Stock Options financial
"Security title listed as ResMed Common Stock Options in the transaction table."
indirect ownership financial
"Ownership type marked indirect via Lisette and Michael Farrell Family Trust."
FAQ
What did ResMed (RMD) CEO Michael Farrell report in this Form 4?
Michael J. Farrell reported exercising 4,991 stock options at $146.34 per share and selling 4,991 ResMed Common Stock shares at a weighted average price of $205.6895 per share on August 7, 2026.
How many ResMed (RMD) options did Michael Farrell exercise and at what price?
He exercised 4,991 ResMed Common Stock options at an exercise price of $146.34 per share. These options first became exercisable on November 11, 2020 and were scheduled to expire on November 21, 2026, vesting one-third per year.
What ResMed (RMD) holdings does Michael Farrell report after these transactions?
After exercising options, he held 14,975 ResMed Common Stock options related to this grant. The filing also reports 2,090 ResMed Common Stock shares held indirectly through the Lisette and Michael Farrell Family Trust as of the reported date.
What is the vesting schedule of the ResMed (RMD) options Michael Farrell exercised?
The footnote explains the options first became exercisable on November 11, 2020 and vest 1/3 per year. These options were scheduled to expire on November 21, 2026, defining the window during which they could be exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
